

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

Cyclophilin B (D1V5J) Rabbit mAb

RRID:AB_2799247

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 43603, RRID:AB_2799247

Antibody Information

URL: http://antibodyregistry.org/AB_2799247

Proper Citation: Cell Signaling Technology Cat# 43603, RRID:AB_2799247

Target Antigen: PPIB

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W

Antibody Name: Cyclophilin B (D1V5J) Rabbit mAb

Description: This monoclonal targets PPIB

Target Organism: h, m, r, mk

Clone ID: Clone D1V5J

Antibody ID: AB_2799247

Vendor: Cell Signaling Technology

Catalog Number: 43603

Record Creation Time: 20250819T210730+0000

Record Last Update: 20250819T215602+0000

Ratings and Alerts

No rating or validation information has been found for Cyclophilin B (D1V5J) Rabbit mAb.

No alerts have been found for Cyclophilin B (D1V5J) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Stanland LJ, et al. (2025) A first-in-class EGFR-directed KRAS G12V selective inhibitor. Cancer cell.

Shah K, et al. (2025) LncRNA SLNCR phenocopies the E2F1 DNA binding site to promote melanoma progression. Cell reports, 44(5), 115608.

Burge RA, et al. (2025) PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer. Cancer research, OF1.

Garland J, et al. (2024) Targeting HSP70-E7 Interaction With SHetA2: A Novel Therapeutic Strategy for Cervical Cancer. Journal of medical virology, 96(11), e70088.

Nasser AM, et al. (2024) CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(14), 2996.

Wofford W, et al. (2024) Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response. Cell reports, 43(8), 114532.

Malik S, et al. (2024) Antitumor efficacy of a sequence-specific DNA-targeted ?PNA-based c-Myc inhibitor. Cell reports. Medicine, 5(1), 101354.

Xu Y, et al. (2024) ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer. Cancer discovery, 14(8), 1496.

Li X, et al. (2023) Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer. Cancer cell, 41(8), 1427.

Xu Y, et al. (2023) ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers. bioRxiv : the preprint server for biology.

Dissanayake LV, et al. (2022) Lack of xanthine dehydrogenase leads to a remarkable renal decline in a novel hypouricemic rat model. iScience, 25(9), 104887.

Du M, et al. (2022) Liquid phase separation of NEMO induced by polyubiquitin chains activates NF-?B. Molecular cell, 82(13), 2415.

Wasmuth EV, et al. (2022) Allosteric interactions prime androgen receptor dimerization and activation. *Molecular cell*, 82(11), 2021.

Zhang Z, et al. (2020) Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. *Cancer cell*, 38(2), 279.